◎ Sugi Atlas

Atlas / Drug / Thyrotropin Alfa

Thyrotropin Alfa

drug
On this page

Also known as GX-30ThyrogenThyrotropin alphaThyrotropine alfaTirotropina alfa

Summary

Thyrotropin Alfa (CHEMBL1201533) is an approved protein (ATC H01AB01) targeting TSHR; indicated across 7 conditions including thyroid gland carcinoma and thyroid tumor.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Protein
  • ATC class: H01AB01
  • Targets: 1 (TSHR)
  • Indications: 7 conditions
  • Clinical trials: 6

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1201533
NameThyrotropin Alfa
TypeProtein
Max phase4
ATCH01AB01

Also known as: GX-30, Thyrogen, Thyrotropin alfa, Thyrotropin alpha, Thyrotropine alfa, Tirotropina alfa, THYROTROPIN ALFA

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
TSHRTSH receptorAgonist0%P16473

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): TSHR.

Top Reactome pathways

2 total, by targets touching each:

PathwayTargetsGenes
Hormone ligand-binding receptors1TSHR
G alpha (s) signalling events1TSHR

Dominant GO biological processes

GO termTargets
cell surface receptor signaling pathway1
G protein-coupled receptor signaling pathway1
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger1
adenylate cyclase-activating G protein-coupled receptor signaling pathway1
cell-cell signaling1
positive regulation of cell population proliferation1
hormone-mediated signaling pathway1
thyroid-stimulating hormone signaling pathway1
positive regulation of cold-induced thermogenesis1
cellular response to glycoprotein1
cellular response to thyrotropin-releasing hormone1
signal transduction1
response to hormone1

Indications & clinical

Indications

7 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
thyroid gland carcinoma4MONDO:0015075EFO:0002892
thyroid tumor4MONDO:0015074EFO:0003841
thyroid gland papillary carcinoma4MONDO:0005075EFO:0000641
nodular goiter2MONDO:0006869EFO:1001062
Graves disease2MONDO:0005364EFO:0004237
thyroid gland follicular carcinoma2MONDO:0005034EFO:0000501

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

PhaseTrials
PHASE32
PHASE41
PHASE21
EARLY_PHASE11
Not specified1

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00001730PHASE4COMPLETEDStudy of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.
NCT00196729PHASE3COMPLETEDComparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration
NCT00435851PHASE3UNKNOWNMedico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients
NCT03841617PHASE2RECRUITINGThe Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
NCT02145143EARLY_PHASE1COMPLETEDEnhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
NCT01736163Not specifiedCOMPLETEDA Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

340 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
ACETAMINOPHENChEMBLPhase 4 (approved)TSHR
ACETOHEXAMIDEChEMBLPhase 4 (approved)TSHR
ACYCLOVIRChEMBLPhase 4 (approved)TSHR
ALCOHOLChEMBLPhase 4 (approved)TSHR
ALLOPURINOLChEMBLPhase 4 (approved)TSHR
AMANTADINEChEMBLPhase 4 (approved)TSHR
AMILORIDEChEMBLPhase 4 (approved)TSHR
AMINOPYRINEChEMBLPhase 4 (approved)TSHR
AMIODARONEChEMBLPhase 4 (approved)TSHR
AMISULPRIDEChEMBLPhase 4 (approved)TSHR
AMOXAPINEChEMBLPhase 4 (approved)TSHR
AMSACRINEChEMBLPhase 4 (approved)TSHR
ANTAZOLINEChEMBLPhase 4 (approved)TSHR
APRACLONIDINEChEMBLPhase 4 (approved)TSHR
ASPIRINChEMBLPhase 4 (approved)TSHR
ATOMOXETINEChEMBLPhase 4 (approved)TSHR
AZELAIC ACIDChEMBLPhase 4 (approved)TSHR
AZITHROMYCINChEMBLPhase 4 (approved)TSHR
BENOXINATEChEMBLPhase 4 (approved)TSHR
BENZBROMARONEChEMBLPhase 4 (approved)TSHR
BENZTHIAZIDEChEMBLPhase 4 (approved)TSHR
BENZYL ALCOHOLChEMBLPhase 4 (approved)TSHR
BERBERINEChEMBLPhase 4 (approved)TSHR
BETAINEChEMBLPhase 4 (approved)TSHR
BISACODYLChEMBLPhase 4 (approved)TSHR
BITHIONOLChEMBLPhase 4 (approved)TSHR
BUMETANIDEChEMBLPhase 4 (approved)TSHR
BUSULFANChEMBLPhase 4 (approved)TSHR
BUTAMBENChEMBLPhase 4 (approved)TSHR
CARBAMAZEPINEChEMBLPhase 4 (approved)TSHR
CARBAMOYLCHOLINEChEMBLPhase 4 (approved)TSHR
CARBETAPENTANEChEMBLPhase 4 (approved)TSHR
CARISOPRODOLChEMBLPhase 4 (approved)TSHR
CARMUSTINEChEMBLPhase 4 (approved)TSHR
CELECOXIBChEMBLPhase 4 (approved)TSHR
CHLORAMBUCILChEMBLPhase 4 (approved)TSHR
CHLORHEXIDINEChEMBLPhase 4 (approved)TSHR
CHLOROTHIAZIDEChEMBLPhase 4 (approved)TSHR
CHLOROTRIANISENEChEMBLPhase 4 (approved)TSHR
CHLORPROPAMIDEChEMBLPhase 4 (approved)TSHR
CHLORZOXAZONEChEMBLPhase 4 (approved)TSHR
CILOSTAZOLChEMBLPhase 4 (approved)TSHR
CIMETIDINEChEMBLPhase 4 (approved)TSHR
CINOXACINChEMBLPhase 4 (approved)TSHR
CLEMASTINEChEMBLPhase 4 (approved)TSHR
CLOFIBRATEChEMBLPhase 4 (approved)TSHR
CLOMIPRAMINEChEMBLPhase 4 (approved)TSHR
CLOTRIMAZOLEChEMBLPhase 4 (approved)TSHR
CLOZAPINEChEMBLPhase 4 (approved)TSHR
COLCHICINEChEMBLPhase 4 (approved)TSHR
CYCLOBENZAPRINEChEMBLPhase 4 (approved)TSHR
CYCLOSERINEChEMBLPhase 4 (approved)TSHR
CYPROHEPTADINEChEMBLPhase 4 (approved)TSHR
CYSTEAMINEChEMBLPhase 4 (approved)TSHR
DACARBAZINEChEMBLPhase 4 (approved)TSHR
DALFAMPRIDINEChEMBLPhase 4 (approved)TSHR
DANTHRONChEMBLPhase 4 (approved)TSHR
DAPSONEChEMBLPhase 4 (approved)TSHR
DAUNORUBICINChEMBLPhase 4 (approved)TSHR
DEBRISOQUINChEMBLPhase 4 (approved)TSHR

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot